All In Biotech

Drug Trial Radar · NCT06340958

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-100 as an Adjunctive Treatment for Major Depressive Disorder Patients With Inadequate Response to Standard Antidepressants

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

99

Actual

Start

Mar 18, 2024

Primary completion

Jun 6, 2025

Study completion Nov 25, 2025

Sponsor

Lead sponsor
Clexio Biosciences Ltd.Industry
Sponsor type
Industry
First posted
Apr 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100 (oral esketamine) for the treatment of MDD in participants currently treated with an oral antidepressant medication and who have an inadequate response to at least 2 antidepressants.

Conditions

  • Adjunctive Treatment of Major Depressive Disorder (MDD)

Interventions

  • CLE-100Drug

    1 tablet of CLE-100 administered once daily

  • PlaceboDrug

    1 tablet of placebo administered once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) ScoreTime frame: 29 days

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site 139

    La Jolla, California

  • Clinical Site 131

    Lafayette, California

  • Clinical Site 130

    Upland, California

  • Clinical Site 102

    Hollywood, Florida

  • Clinical Site 105

    Lauderhill, Florida

  • Clinical Site 140

    Miami Springs, Florida

  • Clinical Site 132

    Pensacola, Florida

  • Clinical Site 118

    Atlanta, Georgia

  • Clinical Site 138

    Marietta, Georgia

  • Clinical Site 114

    Savannah, Georgia

  • Clinical Site 127

    Chicago, Illinois

  • Clinical Site 120

    Elgin, Illinois

  • Clinical Site 108

    Gaithersburg, Maryland

  • Clinical Site 116

    Flowood, Mississippi

  • Clinical Site 126

    O'Fallon, Missouri

  • Clinical Site 101

    Toms River, New Jersey

  • Clinical Site 103

    Beachwood, Ohio

  • Clinical Site 119

    North Canton, Ohio

  • Clinical Site 135

    Oklahoma City, Oklahoma

  • Clinical Site 107

    Austin, Texas

  • Clinical Site 137

    Plano, Texas

  • Clinical Site 117

    Murray, Utah

  • Clinical Site 115

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.